<DOC>
	<DOCNO>NCT01296568</DOCNO>
	<brief_summary>This open-label study conduct determine metabolism physiological disposition radiolabeled LY2603618 single dose patient advance and/or metastatic solid tumor . After minimum 7-day washout period follow [ 14C ] LY2603618 dose , patient allow continue receive continue access LY2603618 combination pemetrexed gemcitabine outpatient .</brief_summary>
	<brief_title>C14 Study Oncology Patients With Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Have histological cytological diagnosis cancer ( solid tumor ) , clinical radiologic evidence locally advance and/or metastatic disease , lifeprolonging therapy exists ( , refractory standard therapy and/or therapy know provide clinical benefit , standard therapy exists ) Note : Patients progressive disease receive pemetrexed metastatic disease exclude receive combination pemetrexed safety extension study . Patients progressive disease receive gemcitabine metastatic disease exclude receive combination gemcitabine safety extension study . Have body surface area great equal 1.37 m^2 Have give write informed consent prior studyspecific procedure Adequate hematologic , hepatic renal function Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous treatment cancer , include chemotherapy , radiotherapy , anticancer hormone therapy , investigational therapy least 30 day prior study entry recover acute effect therapy ( least 42 day mitomycinC nitrosoureas , 60 day monoclonal antibody ) Are reliable willing make available duration study willing follow study procedure Males females reproductive potential : Must agree use medically approve contraceptive precaution study follow last dose study drug , judgment investigator , safe patient become pregnant father child Females childbearing potential : Have negative serum pregnancy test less equal 7 day first dose study drug must also breastfeed Have estimate life expectancy , judgment investigator , permit patient complete 1 full cycle treatment ( beyond initial [ 14C ] LY2603618 dose ) Prior radiation therapy treatment cancer pancreatic allow &lt; 25 % bone marrow patient must recover acute toxic effect treatment prior study enrollment . Prior radiation whole pelvis allow . Prior radiotherapy must complete least 4 week study entry . Have receive treatment within 28 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication Have previously complete withdrawn study study investigate LY2603618 checkpoint kinase one ( Chk1 ) inhibitor Have know allergy gemcitabine , pemetrexed , LY2603618 , ingredient gemcitabine , pemetrexed , LY2603618 ( like Captisol ) Have serious preexist medical condition ( leave discretion investigator ) advance cancer Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Patients treat CNS metastasis eligible study currently receive corticosteroid and/or anticonvulsant , disease asymptomatic radiographically stable least 90 day Have current hematologic malignancy either acute chronic leukemia Have active fungal , bacterial , and/or know viral infection include HIV viral ( A , B , C ) hepatitis ( screen require ) Have QTc interval &gt; 500 msec screen electrocardiogram ( ECG ) Have electrocardiogram ( ECG ) abnormalities screen ECG significant conduction abnormality , ischemic change ( prior Qwave myocardial infarction and/or mark ischemic ST Twave ) , arrhythmia ( persistent paroxysmal ventricular supraventricular arrhythmia , include atrial fibrillation ) , ECG abnormality would put patient unnecessary risk opinion investigator Have participate 14C study within last 6 month prior screen study . The total exposure study previous study must less 5 mSv .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>metastatic solid tumor</keyword>
	<keyword>Malignant/M-Neoplasm</keyword>
	<keyword>Pancreas NOS</keyword>
	<keyword>Absorption</keyword>
	<keyword>Distribution</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
	<keyword>Mass balance</keyword>
	<keyword>Metabolic profile</keyword>
	<keyword>Radiolabeled study</keyword>
</DOC>